Latha Vairavan serves as the Chief Financial Officer at Arcutis Biotherapeutics Inc., a biopharmaceutical company dedicated to developing innovative treatments for immune-mediated inflammatory diseases, with a focus on dermatology. With over two decades of experience in the biotechnology and pharmaceutical industries, Vairavan has established herself as a seasoned financial leader adept at navigating complex funding landscapes and driving sustainable growth. She joined Arcutis in 2021, bringing her expertise to support the company's mission of advancing novel therapies from clinical development to commercialization. Prior to Arcutis, Vairavan held pivotal CFO roles at several high-profile biotech firms, including Kura Oncology, where she spearheaded the company's initial public offering (IPO) and subsequent equity financings that raised over $400 million. Her earlier career included key financial positions at Synthorx (acquired by Sanofi), Relypsa (acquired by Galenica), and InterMune (acquired by Roche), where she played instrumental roles in mergers, acquisitions, and operational turnarounds. Her track record includes successfully managing SEC filings, investor relations, and strategic partnerships that have propelled multiple companies through critical growth phases. At Arcutis, Vairavan oversees all financial operations, including capital raising, budgeting, and risk management, contributing significantly to the company's ZORYVE portfolio expansion and recent commercial milestones. Her strategic foresight has been crucial in securing substantial venture funding and supporting the FDA approval of Arcutis' lead product for plaque psoriasis and atopic dermatitis. Vairavan holds an MBA from the University of California, Berkeley, and a BS in Electrical Engineering from the University of Madras, blending analytical rigor with business acumen.